Engineering Polysaccharide-Based Polymeric Micelles to Enhance Permeability of Cyclosporin A Across Caco-2 Cells
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
To assess and compare the effectiveness of two types of polysaccharide-based micelles as delivery vehicles for poorly water soluble drugs by monitoring their permeability across Caco-2 cell monolayers.
Dextran (DEX) and hydroxypropylcellulose (HPC) were hydrophobically modified (HM) by grafting polyoxyethylene cetyl ether (POE-C16, 15 mol% and 5.4 mol%, respectively). The onset of micellization and mean diameter of polymeric micelles formed by HM-DEX and HM-HPC were determined by fluorescence spectroscopy and dynamic light scattering, respectively. Cyclosporin A (CsA)-loaded polymeric micelles were prepared by a dialysis procedure, and the amount of incorporated CsA was assayed by high performance liquid chromatography (HPLC). The stability of micelles in simulated gastric and intestinal fluids was studied as a function of contact time, and their cytotoxicity toward Caco-2 cells was evaluated using the MTT colorimetric assay. The bidirectional transport across Caco-2 cell monolayers of CsA entrapped in HM-DEX and HM-HPC micelles and of the polymers themselves was evaluated in the presence and absence of P-glycoprotein inhibitor.
The amount of CsA incorporated in HM-HPC and HM-DEX micelles reached 5.5 and 8.5% w/w, respectively (entrapment efficiency of 22% or more). The polymeric micelles exhibited high stability in gastric and intestinal fluids and no significant cytotoxicity toward Caco-2 cells. The apical to basal permeability of CsA across Caco-2 cells increased significantly when loaded in polymeric micelles compared to free CsA.
Polysaccharide-based polymeric micelles are promising carriers for the oral delivery of poorly water soluble drugs. In vitro tests indicate that, overall, HM-HPC micelles are more effective compared to HM-DEX micelles.
- 1. R. M. Merion, D. J. White, S. Thiru, D. D. Evans, and R. Y. Calne. Cyclosporine: five years experience in cadaveric renal transplantation. N. Engl. J. Med. 310:148–154 (1984).
- 2. I. J. Klompmaker, J. M. Wierda, W. J. Sluiter, D. R. Uges, E. B. Haagsma, R. Verwer, and M. J. Slooff. Pharmacokinetics of cyclosporine A after intravenous and oral administration in liver transplant patients measured with high-performance liquid chromatography. Ther. Drug Monit. 15:60–64 (1993).
- 3. F. Galla, V. Marzocchi, L. Croattino, D. Poz, M. Baraldo, and M. Furlanut. Oral and intravenous disposition of cyclosporine in psoriatic patients. Ther. Drug Monit. 17:302–304 (1995).
- 4. A. C. Foradori, L. Martinez, A. Vacarezza, L. Elberg, A. Loveluck, and C. Pinto. Pharmacokinetics of a new galenical formulation of oral cyclosporine A in stable kidney transplanted patients. Transplant. Proc. 26:2969–2972 (1994).
- 5. I. S. Sketris, J. G. Lawen, L. Beauregard-Zollinger, P. Belitsky, D. Landsberg, M. L. Givner, and P. Keown. Comparison of the pharmacokinetics of cyclosporine sandimmune with sandimmune neoral in stable renal transplant patients. Transplant. Proc. 26: 2961–2963 (1994).
- 6. D. M. Woodcock, S. Jefferson, M. E. Linsenmeyer, P. J. Crowther, G. M. Chojnowski, B. Williams, and I. Bertoncello. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res. 50:4199–4203 (1990).
- 7. F. Seeballuck, M. B. Ashford, and C. M. O’Driscoll. The effects of Pluronics block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells. Pharm. Res. 20:1085–1092 (2003).
- 8. J. Mason. Renal side-effects of cyclosporin A. Br. J. Dermatol. 122:71–77 (1990).
- 9. K. L. Skorecki, W. P. Rutledge, and R. W. Schrier. Acute cyclosporine nephrotoxicity-prototype for a renal membrane signalling disorder. Kidney Int. 42:1–10 (1992).
- 10. L. S. Friedman, J. L. Dienstag, P. W. Nelson, P. S. Russell, and A. B. Cosimi. Anaphylactic reaction and cardiopulmonary arrest following intravenous cyclosporine. Am. J. Med. 78:343–345 (1985).
- 11. D. L. Howrie, R. J. Ptachcinski, B. P. Griffith, R. J. Hardesty, J. T. Rosenthal, G. J. Burckart, and R. Venkataramanan. Anaphylactoid reactions associated with parenteral cyclosporine use: possible role of Cremophor EL. Drug Intell. Clin. Pharm. 19: 425–427 (1985).
- 12. C. Allen, D. Maysinger, and A. Eisenberg. Nano-engineering block copolymer aggregates for drug delivery. Colloids Surf. B Biointerfaces 16:3–27 (1999).
- 13. X. Chen, T. Young, M. Sarkari, R. Williams, and K. Johnston. Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution. Int. J. Pharm. 242:3–14 (2002).
- 14. A. Sanchez and M. J. Alonso. Poly(D,L-lactide-co-glycolide) micro and nanospheres as a way to prolong blood/plasma levels of subcutaneously injected cyclosporin A. Eur. J. Pharm. Biopharm. 41:31–37 (1995).
- 15. K. Itoh, A. Pongpeerapat, Y. Tozuka, T. Oguchi, and K. Yamamoto. Nanoparticle formation of poorly water-soluble drugs from ternary ground mixtures with PVP and SDS. Chem. Pharm. Bull. (Tokyo) 51:171–174 (2003).
- 16. M. Al-Meshal, S. H. Khidr, M. A. Bayomi, and A. A. Al-Angary. Oral administration of liposomes containing cyclosporine: a pharmacokinetic study. Int. J. Pharm. 168:163–168 (1998).
- 17. B. Ozpolat, G. Lopez-Berestein, P. Adamson, C. J. Fu, and A. H. Williams. Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers. J. Pharm. Pharm. Sci. 6:292–301 (2003).
- 18. F. Nacka, M. Cansell, P. Meleard, and N. Combe. Incorporation of alpha-tocopherol in marine lipid-based liposomes: in vitro and in vivo studies. Lipids 36:1313–1320 (2001).
- 19. M. C. Taira, N. S. Chiaramoni, K. M. Pecuch, and S. Alonso-Romanowski Stability of liposomal formulations in physiological conditions for oral drug delivery. Drug Deliv. 11:123–128 (2004).
- 20. S. Bonduelle, M. Carrier, C. Pimienta, J. P. Benoit, and V. Lenaerts. Tissue concentration of nanoencapsulated radiolabelled cyclosporin following peroral delivery in mice or ophthalmic application in rabbits. Eur. J. Pharm. Biopharm. 42:313–319 (1996).
- 21. J. Molpeceres, M. R. Aberturas, and M. Guzman. Biodegradable nanoparticles as a delivery system for cyclosporine: preparation and characterization. J. Microencapsul. 17:599–614 (2000).
- 22. E. Ugazio, R. Cavalli, and M. R. Gasco. Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int. J. Pharm. 241: 341–344 (2002).
- 23. J. Daia, T. Nagaib, X. Wanga, T. Zhangc, M. Menga, and Q. Zhang. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int. J. Pharm. 280:229–240 (2004).
- 24. M. P. Desai, V. Labhasetwar, G. L. Amidon, and R. J. Levy. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 13:1838–1845 (1996).
- 25. M. C. Varela, M. Guzman, J. Molpeceres, M. D. R. Aberturas, D. Rodriguez-Puyol, and M. Rodriguez-Puyol. Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats. Eur. J. Pharm. Sci. 12:471–478 (2001).
- 26. R. Gref, P. Quellec, A. Sanchez, P. Calvo, E. Dellacherie, and M. J. Alonso. Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers. Eur. J. Pharm. Biopharm. 51:111–118 (2001).
- 27. A. M. De Campos, A. Sanchez, and M. J. Alonso. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. 224:159–168 (2001).
- 28. G. Sertsou, J. Butler, J. Hempenstall, and T. Rades. Solvent change co-precipitation with hydroxypropyl methylcellulose phthalate to improve dissolution characteristics of a poorly water-soluble drug. J. Pharm. Pharmacol. 54:1041–1047 (2002).
- 29. M. F. Francis, L. Lavoie, F. M. Winnik, and J. C. Leroux. Solubilization of cyclosporin A in dextran-g-polyethyleneglycolalkyl ether polymeric micelles. Eur. J. Pharm. Biopharm. 56:337–346 (2003).
- 30. M. F. Francis, M. Piredda, and F. M. Winnik. Solubilization of poorly water soluble drugs in micelles of hydrophobically modified hydroxypropylcellulose copolymers. J. Control. Rel. 93: 59–68 (2003).
- 31. D. D. Lasic. Mixed micelles in drug delivery. Nature 355:279–280 (1992).
- 32. H. E. J. Hofland, J. A. Bouwstra, J. C. Verhoef, G. Buckton, B. Z. Chowdry, M. Ponec, and H. E. Junginger. Safety aspects of non-ionic surfactant vesicles-a toxicity study related to the physicochemical characteristics of non-ionic surfactants. J. Pharm. Pharmacol. 44:287–294 (1992).
- 33. B. G. Yu, T. Okano, K. Kataoka, S. Sardari, and G. S. Kwon. In vitro dissociation of antifungal efficacy and toxicity for amphotericin B-loaded poly(ethylene oxide)-block-poly(beta benzyl L-aspartate) micelles. J. Control. Rel. 56:285–291 (1998).
- 34. S. C. Kim, D. W. Kim, Y. H. Shim, J. S. Bang, H. S. Oh, S. W. Kim, and M. H. Seo. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J. Control. Rel. 72:191–202 (2001).
- 35. R. Jevprasesphant, J. Penny, D. Attwood, N. B. McKeown, and A. D’Emanuele. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm. Res. 20: 1543–1550 (2003).
- 36. C. Larsen. Dextran prodrugs-structure and stability in relation to therapeutic activity. Adv. Drug Deliv. Rev. 3:103–154 (1989).
- 37. N. P. Couch. The clinical status of low molecular weight dextran: a critical review. Clin. Pharmacol. Ther. 6:656–665 (1965).
- 38. J. P. Draye, B. Delaey, A. Van de Voorde, A. Van Den Bulcke, B. Bogdanov, and E. Schacht. In vitro release characteristics of bioactive molecules from dextran dialdehyde cross-linked gelatin hydrogel films. Biomaterials 19:99–107 (1998).
- 39. I. S. Kim, Y. I. Jeong, and S. H. Kim. Self-assembled hydrogel nanoparticles composed of dextran and poly(ethylene glycol) macromer. Int. J. Pharm. 205:109–116 (2000).
- 40. Y. Zhang and C. C. Chu. Biodegradable dextran-polylactide hydrogel networks: their swelling, morphology and the controlled release of indomethacin. J. Biomed. Mater. Res. 59:318–328 (2002).
- 41. R. Mehvar. Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J. Control. Rel. 69:1–25 (2000).
- 42. V. Pade and S. Stavchansky. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm. Res. 14:1210–1215 (1997).
- 43. K. L. Audus, R. L. Bartel, I. J. Hidalgo, and R. T. Borchardt. The use of cultured epithelial and endothelial cells for drug transport and metabolism studies. Pharm. Res. 7:435–451 (1990).
- 44. I. J. Hidalgo, T. J. Raub, and R. T. Borchardt. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96: 736–749 (1989).
- 45. J. N. Cogburn, M. G. Donovan, and C. S. Schasteen. A model of human small intestinal absorptive cells. 1. Transport barrier. Pharm. Res. 8:210–216 (1991).
- 46. F. Delie and R. Werner. A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. Crit. Rev. Ther. Drug Carrier Syst. 14:221–286 (1997).
- 47. P. Artursson, K. Palm, and K. Luthman. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 46:27–43 (2001).
- 48. K. I. Hosoya, K. J. Kim, and V. H. Lee. Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers. Pharm. Res. 13:885–890 (1996).
- 49. J. Hunter and B. H. Hirst. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv. Drug Deliv. Rev. 25:129–157 (1997).
- 50. P. Artursson and R. T. Borchardt. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm. Res. 14: 1655–1658 (1997).
- 51. G. krishna. K. J. Chen, C. C. Lin and A. A. Nomeir. Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2. Int. J. Pharm. 222:77–89 (2001).
- 52. W. Kamm, A. Jonczyk, T. Jung, G. Luckenbach, P. Raddatz, and T. Kissel. Evaluation of absorption enhancement for a potent cyclopeptidic alpha(nu)beta(3)-antagonist in a human intestinal cell line (Caco-2). Eur. J. Pharm. Sci. 10:205–214 (2000).
- 53. F. Faassen, J. Kelder, J. Lenders, R. Onderwater, and H. Vromans. Physicochemical properties and transport of steroids across Caco-2 cells. Pharm. Res. 20:177–186 (2003).
- 54. P. Artursson, and J. Karlsson. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175:880–885 (1991).
- 55. S. Yee. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man: fact or myth. Pharm. Res. 14:763–766 (1997).
- 56. S. Yamashita, Y. Tanaka, Y. Endoh, Y. Taki, T. Sakane, T. Nadai, and H. Sezaki. Analysis of drug permeation across Caco-2 monolayer: implication for predicting in vivo drug absorption. Pharm. Res. 14:486–491 (1997).
- 57. Y. Tezuka, K. Imai, M. Oshima, and T. Chiba. Determination of substituent distribution in cellulose ethers by 13C- and 1H-NMR studies of their acetylated derivatives: O-(2-hydroxypropyl) cellulose. Carbohydr. Res. 196:1–10 (1990).
- 58. M. G. Wirick and M. H. Waldman. Some solution properties of fractionated water-soluble hydroxypropylcellulose. J. Appl. Polym. Sci. 14:579–597 (1970).
- 59. M. F. Francis, M. Cristea, and F. M. Winnik. Polymeric micelles for oral drug delivery: why and how. Pure Appl. Chem. 76: 1321–1335 (2004).
- 60. D. Blakeslee. Immunofluorescence using dichlorotriazinylaminofluorescein (DTAF). II. Preparation, purity and stability of the compound. J. Immunol. Methods 17:361–364 (1977).
- 61. C. L. Zhao, M. A. Winnik, G. Riess, and M. D. Croucher. Fluorescence probe techniques used to study micelle formation in water-soluble block copolymers. Langmuir 6:514–516 (1990).
- 62. T. Mosmann. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55–63 (1983). CrossRef
- 63. M. B. Hansen, S. E. Nielsen, and K. Berg. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119:203–210 (1989).
- 64. C. A. Bailey, P. Bryla, and A. W. Malick. The use of the intestinal epithelial cell culture model, Caco-2, in pharmaceutical development. Adv. Drug Deliv. Rev. 22:85–103 (1996).
- 65. M. M. Nerurkar, P. S. Burton, and R. T. Borchardt. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res. 13:528–534 (1996).
- 66. E. V. Batrakova, H. Y. Han, V. Y. Alakhov, D. W. Miller, and A. V. Kabanov. Effects of pluronic block copolymers on drug absorption in Caco-2 cell monolayers. Pharm. Res. 15:850–855 (1998).
- 67. E. V. Batrakova, H. Y. Han, D. W. Miller, and A. V. Kabanov. Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells. Pharm. Res. 15: 1525–1532 (1998).
- 68. P. Augustijns, T. P. Bradshaw, L. S. Gan, R. W. Hendren, and D. R. Thakker. Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Commun. 197:360–365 (1993).
- 69. G. Fricker, J. F. Drewe, J. Huwyler, H. Gutmann, and C. Beglinger. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br. J. Pharmacol. 118: 1841–1847 (1996).
- 70. Y. Y. Chiu, K. Higaki, B. L. Neudeck, J. L. Barnett, L. S. Welage, and G. L. Amidon. Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm. Res. 20:749–756 (2003).
- 71. D. W. Miller, E. V. Batrakova, T. O. Waltner, V. Y. Alakhov, and A. V. Kabanov. Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption. Bioconjugate Chem. 8:649–657 (1997).
- 72. V. J. Wacher, J. A. Silverman, Y. Zhang, and L. Z. Benet. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87:1322– 1330 (1998).
- 73. E. V. Batrakova, S. Li, D. W. Miller, and A. Kabanov. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res. 16: 1366–1372 (1999).
- 74. R. Wiwattanapatapee, B. Carreno-Gomez, N. Malik, and R. Duncan. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system? Pharm. Res. 17:991–998 (2000).
- 75. M. El-Sayed, M. Ginski, C. Rhodes, and H. Ghandehari. Trans-epithelial transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers. J. Control. Rel. 81:355–365 (2002).
- 76. M. El-Sayed, C. A. Rhodes, M. Ginski, and H. Ghandehari. Transport mechanism(s) of poly (amidoamine) dendrimers across Caco-2 cell monolayers. Int. J. Pharm. 265:151–157 (2003).
- 77. P. Jani, G. W. Halbert, J. Langridge, and A. T. Florence. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol. 42:821–826 (1990).
- 78. J. P. Ebel. A method for quantifying particle absorption from the small intestine of the mouse. Pharm. Res. 7:848–851 (1990).
- 79. L. Simon, G. Shine, and A. D. Dayan. Translocation of particulates across the gut wall - a quantitative approach. J. Drug Target. 3:217–219 (1995).
- 80. K. E. Carr, R. A. Hazzard, S. Reid, and G. M. Hodges. The effect of size on uptake of orally administered latex microparticles in the small intestine and transport to mesenteric lymph nodes. Pharm. Res. 13:1205–1209 (1996).
- 81. A. T. Florence and N. Hussain. Trancytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv. Drug Deliv. Rev. 50:S69–S89 (2001).
- 82. Y. Miyazaki, S. Yakou, T. Nagai, and K. Takayama. Release profiles of theophylline from microspheres consisting of dextran derivatives and cellulose acetate butyrate: effect of polyion complex formation. Drug Dev. Ind. Pharm. 29:795–804 (2003).
- 83. G. Ponchel. and J. Irache. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliv. Rev. 34:191–219 (1998).
- 84. J. K. Vasir, K. Tambwekar, and S. Garg. Bioadhesive micro-spheres as a controlled drug delivery system. Int. J. Pharm. 255: 13–32 (2003).
- Engineering Polysaccharide-Based Polymeric Micelles to Enhance Permeability of Cyclosporin A Across Caco-2 Cells
Volume 22, Issue 2 , pp 209-219
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links
- cyclosporin A
- oral delivery
- polymeric micelles
- Industry Sectors
- Author Affiliations
- 1. Faculty of Pharmacy, University of Montreal, Montreal, Quebec, H3C 3J7, Canada
- 2. “Petru Poni”, Institute of Macromolecular Chemistry, Iasi, 700487, Romania
- 3. Department of Chemistry, University of Montreal, Montreal, Quebec, H3C 3J7, Canada